VITAMIN K1- phytonadione injection, emulsion
Hospira, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use VITAMIN K_1 INJECTION safely and effectively. See full prescribing information for VITAMIN K_1 INJECTION.

VITAMIN K_1 INJECTION (Phytonadione Injectable Emulsion, USP), for intravenous, intramuscular, and subcutaneous use.
Initial U.S. Approval: 1960

WARNING: HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE

See full prescribing information for complete boxed warning.

Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after INTRAVENOUS and INTRAMUSCULAR injection of Vitamin K_1 Injection. Reactions have occurred despite dilution to avoid rapid infusion and upon first and subsequent doses. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified. (5.1)

INDICATIONS AND USAGE

Vitamin K_1 Injection is a vitamin K replacement indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.

- Anticoagulant-induced hypoprothrombinemia deficiency caused by coumarin or indanedione derivatives. (1.1)
- Hypoprothrombinemia due to antibacterial therapy. (1.1)
- Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis. (1.1)
- Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. (1.1)

Vitamin K_1 Injection is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates. (1.2)

DOSAGE AND ADMINISTRATION

- Administer Vitamin K_1 Injection by the subcutaneous route, whenever possible. (2.1)
- When intravenous administration is unavoidable, inject the drug very slowly, not exceeding 1 mg per minute. (2.1)

DOSAGE FORMS AND STRENGTHS

Injection: 1 mg/0.5 mL and 10 mg/mL single-dose ampuls. (3)

CONTRAINDICATIONS

Hypersensitivity to any component of this medication. (4)

WARNINGS AND PRECAUTIONS

- Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative: Use benzyl alcohol-free phytonadione formulations in neonates and infants, if available. (5.2)
- Cutaneous Reactions: May occur with parenteral use. Discontinue drug and manage medically. (5.3)

ADVERSE REACTIONS

Most common adverse reactions are cyanosis, diaphoresis, dizziness, dysgeusia, dyspnea, flushing, hypotension and tachycardia. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Anticoagulants: May induce temporary resistance to prothrombin-depressing anticoagulants. (7)

USE IN SPECIFIC POPULATIONS

- Pregnancy: If available, use a preservative-free phytonadione formulation in pregnant women. (8.1)
- Lactation: If available, use a preservative-free phytonadione formulation in lactating women. (8.2)
- Pediatric Use: The safety and effectiveness of Vitamin K_1 Injection in pediatric patients from 6 months to 17 years have not been established. (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 10/2025

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE

1 INDICATIONS AND USAGE
- 1.1 Treatment of Hypoprothrombinemia Due to Vitamin K Deficiency or Interference
- 1.2 Prophylaxis and Treatment of Vitamin K-Deficiency Bleeding in Neonates

2 DOSAGE AND ADMINISTRATION
- 2.1 Dosing Considerations
- 2.2 Recommended Dosage for Coagulation Disorders from Vitamin K Deficiency or Interference
- 2.3 Recommended Dosage for Prophylaxis and Treatment of Vitamin K Deficiency Bleeding in Neonates
- 2.4 Directions for Dilution

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS
- 5.1 Hypersensitivity Reactions
- 5.2 Risk of Serious Adverse Reaction in Infants due to Benzyl Alcohol Preservative
- 5.3 Cutaneous Reactions
- 5.4 Aluminum Toxicity

6 ADVERSE REACTIONS
- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS
- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE

Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after intravenous and intramuscular injection of Vitamin K_1 Injection. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified *[see Warnings and Precautions (5.1)]*.

1 INDICATIONS AND USAGE

1.1 Treatment of Hypoprothrombinemia Due to Vitamin K Deficiency or Interference

Vitamin K_1 Injection is indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity:

- anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives;
- hypoprothrombinemia due to antibacterial therapy;
- hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis;
- other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.

1.2 Prophylaxis and Treatment of Vitamin K-Deficiency Bleeding in Neonates

Vitamin K_1 Injection is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates.

2 DOSAGE AND ADMINISTRATION

2.1 Dosing Considerations

Whenever possible, administer Vitamin K_1 Injection by the subcutaneous route *[see Boxed Warning]*. When intravenous administration is unavoidable, inject the drug very slowly, not exceeding 1 mg per minute *[see Warnings and Precautions (5.1)]*.

Monitor international normalized ratio (INR) regularly and as clinical conditions indicate. Use the lowest effective dose of Vitamin K_1 Injection.

The coagulant effects of Vitamin K_1 Injection are not immediate; improvement of INR may take 1 to 8 hours. Interim use of whole blood or component therapy may also be necessary if bleeding is severe.

Whenever possible, administer benzyl alcohol-free phytonadione formulations in pediatric patients *[see Warnings and Precautions (5.2), Use in Specific Populations (8.4)]*.

When Vitamin K_1 Injection is used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Vitamin K_1 Injection is not a clotting agent, but overzealous therapy with Vitamin K_1 Injection may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and INR should be checked regularly as clinical conditions indicate.

2.2 Recommended Dosage for Coagulation Disorders from Vitamin K Deficiency or Interference

The recommended dosage of Vitamin K_1 Injection is based on whether the hypoprothrombinemia is anticoagulant-induced (e.g., due to coumarin or indanedione derivatives) or non-anticoagulant-induced (e.g., due to antibiotics; salicylates or other drugs; factors limiting absorption or synthesis) as follows:

- Anticoagulant-Induced Hypoprothrombinemia: Vitamin K_1 Injection 2.5 mg to 10 mg or more subcutaneously, intramuscularly, or intravenously. Up to 25 mg to 50 mg may be administered as a single dose.

Repeated large doses of Vitamin K_1 Injection are not warranted in liver disease if the initial response is unsatisfactory. Failure to respond to Vitamin K_1 Injection may indicate that the condition being treated is inherently unresponsive to Vitamin K_1 Injection.

- Hypoprothrombinemia Due to Other Causes (Non-Anticoagulation-Induced Hypoprothrombinemia): Vitamin K_1 Injection 2.5 mg to 25 mg or more intravenously, intramuscularly, or subcutaneously. Up to 50 mg may be administered as a single dose.

Evaluate INR after 6 to 8 hours, and repeat dose if INR remains prolonged. Modify subsequent dosage (amount and frequency) based on the INR or clinical condition.

2.3 Recommended Dosage for Prophylaxis and Treatment of Vitamin K Deficiency Bleeding in Neonates

Prophylaxis of Vitamin K-Deficiency Bleeding in Neonates

The recommended dosage of Vitamin K_1 Injection is 0.5 mg to 1 mg within one hour of birth for a single dose.

Treatment of Vitamin K Deficiency Bleeding in Neonates

The recommended dosage of Vitamin K_1 Injection is 1 mg given either subcutaneously or intramuscularly. Consider higher doses if the mother has been receiving oral

anticoagulants.

A failure to respond (shortening of the INR in 2 to 4 hours) may indicate another diagnosis or coagulation disorder.

2.4 Directions for Dilution

Dilute Vitamin K_1 Injection with 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or 5% Dextrose and Sodium Chloride Injection. Avoid use of other diluents that may contain benzyl alcohol, which can cause serious toxicity in newborns or low birth weight infants *[see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].*

When diluted, start administration of Vitamin K_1 Injection immediately after dilution. Discard unused portions of diluted solution as well as unused contents of the ampul.

Protect Vitamin K_1 Injection from light at all times.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

3 DOSAGE FORMS AND STRENGTHS

Injection: 1 mg/0.5 mL and 10 mg/mL single-dose ampuls.

4 CONTRAINDICATIONS

Hypersensitivity to phytonadione or any other component of this medication *[see Warnings and Precautions (5.1)]*.

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Fatal and severe hypersensitivity reactions, including anaphylaxis, have occurred with intravenous or intramuscular administration of Vitamin K_1 Injection. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. These reactions have included shock, cardiorespiratory arrest, flushing, diaphoresis, chest pain, tachycardia, cyanosis, weakness, and dyspnea. Administer Vitamin K_1 Injection subcutaneously whenever feasible. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified *[see Dosage and Administration (2.1)]*.

5.2 Risk of Serious Adverse Reaction in Infants due to Benzyl Alcohol Preservative

Use benzyl alcohol-free phytonadione formulations in neonates and infants, if available. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol-preserved drugs, including Vitamin K_1 Injection. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations.

When prescribing Vitamin K_1 Injection in infants, consider the combined daily metabolic

load of benzyl alcohol from all sources including Vitamin K_1 Injection (contains 9 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known *[see Use in Specific Populations (8.1, 8.2 and 8.4)]*.

5.3 Cutaneous Reactions

Parenteral administration of vitamin K replacements (including Vitamin K_1 Injection) may cause cutaneous reactions. Reactions have included eczematous reactions, scleroderma-like patches, urticaria, and delayed-type hypersensitivity reactions. Time of onset ranged from 1 day to a year after parenteral administration. Discontinue Vitamin K_1 Injection for skin reactions and institute medical management.

5.4 Aluminum Toxicity

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Hypersensitivity Reactions *[see Warnings and Precautions (5.1)]*
- Cutaneous Reactions *[see Warnings and Precautions (5.3)]*

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Vitamin K_1 Injection. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiac Disorders: Tachycardia, hypotension.

General Disorders and Administration Site Conditions: Generalized flushing; pain, swelling, and tenderness at injection site.

Hepatobiliary Disorders: Hyperbilirubinemia.

Immune System Disorders: Fatal hypersensitivity reactions, anaphylactic reactions.

Neurologic: Dysgeusia, dizziness.

Pulmonary: Dyspnea.

Skin and Subcutaneous Tissue Disorders: Erythema, pruritic plaques, scleroderma-like lesions, erythema perstans.

Vascular: Cyanosis.

7 DRUG INTERACTIONS

Anticoagulants

Vitamin K_1 Injection may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of Vitamin K_1 Injection are used. Should this occur, higher doses of anticoagulant therapy may be needed when resuming anticoagulant therapy, or a change in therapy to a different class of anticoagulant may be necessary (i.e., heparin sodium).

Vitamin K_1 Injection does not affect the anticoagulant action of heparin.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Vitamin K_1 Injection contains benzyl alcohol, which has been associated with gasping syndrome in neonates. The preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants. If Vitamin K_1 Injection is needed during pregnancy, consider using a benzyl alcohol-free phytonadione formulation *[see Warnings and Precautions (5.2), Use in Specific Populations (8.4)]*.

Published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes *[see Data].* There are maternal and fetal risks associated with vitamin K deficiency during pregnancy *[see Clinical Considerations]*. Animal reproduction studies have not been conducted with phytonadione.

The estimated background risk for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Disease-associated Maternal and/or Embryo/Fetal Risk

Pregnant women with vitamin K deficiency hypoprothrombinemia may be at an increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery. Subclinical maternal vitamin K deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage.

Data

Human Data

Phytonadione has been measured in cord blood of infants whose mothers were treated with phytonadione during pregnancy in concentrations lower than seen in maternal plasma. Administration of vitamin K_1 to pregnant women shortly before delivery increased both maternal and cord blood concentrations. Published data do not report a clear association with phytonadione and adverse maternal or fetal outcomes when used during pregnancy. However, these studies cannot definitively establish the absence of any risk because of methodologic limitations including small sample size and lack of blinding.

Animal Data

In pregnant rats receiving vitamin K_1 orally, fetal plasma and liver concentrations increased following administration, supporting placental transfer.

8.2 Lactation

Risk Summary

Vitamin K_1 Injection contains benzyl alcohol. If available, a preservative-free phytonadione formulation is recommended when Vitamin K_1 Injection is needed during lactation *[see Warnings and Precautions (5.2), Use in Specific Populations (8.4)]*.

Phytonadione is present in breastmilk. There are no data on the effects of Vitamin K_1 Injection on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for Vitamin K_1 Injection and any potential adverse effects on the breastfed child from Vitamin K_1 Injection or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of Vitamin K_1 Injection for prophylaxis and treatment of vitamin K deficiency have been established in neonates. Use of phytonadione injection for prophylaxis and treatment of vitamin K deficiency is based on published clinical studies.

Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and infants in the intensive care unit who received drugs containing benzyl alcohol as a preservative. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol.

When prescribing Vitamin K_1 Injection in infants consider the combined daily metabolic load of benzyl alcohol from all sources including Vitamin K_1 Injection (Vitamin K_1 Injection contains 9 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known *[see Warnings and Precautions (5.2)]*.

Whenever possible, use preservative-free phytonadione formulations in neonates. The preservative benzyl alcohol has been associated with serious adverse events and death in pediatric patients. Premature and low birth weight infants may be more likely to develop toxicity.

10 OVERDOSAGE

Hemolysis, jaundice, and hyperbilirubinemia in newborns, particularly in premature infants, may result from Vitamin K_1 Injection overdose.

11 DESCRIPTION

Phytonadione is a vitamin K replacement, which is a clear, yellow to amber, viscous, odorless or nearly odorless liquid. It is insoluble in water, soluble in chloroform and slightly soluble in ethanol. It has a molecular weight of 450.70.

Phytonadione is 2-methyl-3-phytyl-1, 4-naphthoquinone. Its empirical formula is $C_{31}H_{46}O_2$ and its molecular structure is:



Vitamin K_1 Injection (Phytonadione Injectable Emulsion, USP) is a yellow, sterile, nonpyrogenic aqueous dispersion available for injection by the intravenous, intramuscular and subcutaneous routes. Vitamin K_1 Injection is available in 1 mg (1 mg/0.5 mL) and 10 mg (10 mg/mL) single-dose ampuls. Each milliliter contains phytonadione 2 mg or 10 mg, polyoxyethylated fatty acid derivative 70 mg, dextrose, hydrous 37.5 mg in water for injection; benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment. pH is 6.3 (5.0 to 7.0). Phytonadione is oxygen sensitive.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Vitamin K_1 Injection aqueous dispersion of vitamin K_1 for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the

post-translational carboxylation of multiple, specific, peptide-bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X. The resulting gamma-carboxy-glutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood.

In normal animals and humans, phytonadione is virtually devoid of activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function, that is, to promote the hepatic biosynthesis of vitamin K dependent clotting factors.

12.2 Pharmacodynamics

The action of the aqueous dispersion, when administered intravenously, is generally detectable within an hour or two and hemorrhage is usually controlled within 3 to 6 hours. A normal INR may often be obtained in 12 to 14 hours.

12.3 Pharmacokinetics

Absorption

Phytonadione is readily absorbed following intramuscular administration.

Distribution

After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues.

Elimination

Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies of carcinogenicity, genotoxicity or impairment of fertility have not been conducted with phytonadione.

16 HOW SUPPLIED/STORAGE AND HANDLING

Vitamin K_1 Injection (Phytonadione Injectable Emulsion, USP) is a yellow, sterile, nonpyrogenic aqueous dispersion and is supplied as follows:

Unit of Sale	Concentration
NDC 0409-9157-01 Bundle of 5 clamcells containing 5 single-dose ampuls	1 mg/0.5 mL
NDC 0409-9158-01 Bundle of 5 clamcells containing 5 single-dose ampuls	10 mg/mL

Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.]

Protect from light. Keep ampuls in tray until time of use.

17 PATIENT COUNSELING INFORMATION

Inform the patient of the following important risks of Vitamin K_1 Injection:

Serious Hypersensitivity Reactions

Advise the patient and caregivers to immediately report signs of hypersensitivity after receiving Vitamin K_1 Injection *[see Warnings and Precautions (5.1)].*

Risk of Gasping Syndrome Due to Benzyl Alcohol

Advise the patient and caregivers of the risk of gasping syndrome associated with the use of products that contain benzyl alcohol (including Vitamin K_1 Injection) in neonates, infants, and pregnant women *[see Warnings and Precautions (5.2)].*

Cutaneous Reactions

Advise the patient and caregivers to report the occurrence of new rashes after receiving Vitamin K_1 Injection. These reactions may be delayed for up to a year after treatment *[see Warnings and Precautions (5.3)].*

This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

Hospira

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA

LAB-1141-3.0

PRINCIPAL DISPLAY PANEL - 0.5 mL Ampul Label

NDC 0409-9157-31
0.5 mL Single-dose Ampul

Rx only

VITAMIN K_1 Inj.
(Phytonadione Injectable
Emulsion, USP)

1 mg/0.5 mL
Neonatal Concentration

Contains no more than 100 mcg/L
of aluminum. Protect from light.
Dist. by Hospira, Inc.,

Lake Forest, IL 60045 USA

Hospira

PAA244659

AA####
YYYY-MMM



PRINCIPAL DISPLAY PANEL - 0.5 mL Ampul Tray Label

0.5 mL Single-dose Ampul

Rx only NDC 0409-9157-50
Contains 5 of NDC 0409-9157-31

VITAMIN K_1 Injection
(Phytonadione Injectable Emulsion, USP)

1 mg/0.5 mL
Neonatal Concentration

Protect from light. Keep ampuls in tray until time of use. For Intramuscular, Subcutaneous, or Intravenous (with caution).
Each mL contains phytonadione 2 mg; polyoxyethylated fatty acid

derivative 70 mg; dextrose, hydrous 37.5 mg; benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment. pH 6.3 (5.0 to 7.0). DOSAGE: See Prescribing Information. Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.]
Distributed by Hospira, Inc.
Lake Forest, IL 60045 USA

Hospira

PAA244658

PRINCIPAL DISPLAY PANEL - 1 mL Ampul Label

NDC 0409-9158-31
1 mL only Single-dose Ampul

VITAMIN K_1 Inj.
(Phytonadione Injectable
Emulsion, USP)

10 mg/mL

Contains no more than 110 mcg/L
of aluminum. Protect from light.

Dist. by Hospira, Inc.
Lake Forest, IL 60045 USA

Rx only

PAA244656

AA####
YYYY-MMM



PRINCIPAL DISPLAY PANEL - 1 mL Ampul Tray Label

1 mL Single-dose Ampul

Rx only NDC 0409-9158-50
Contains 5 of NDC 0409-9158-31

VITAMIN K_1 Injection
(Phytonadione Injectable Emulsion, USP)

10 mg/mL

Protect from light. Keep ampuls in tray until time of use. For Intramuscular, Subcutaneous, or Intravenous (with caution).

Each mL contains phytonadione 10 mg; polyoxyethylated fatty acid derivative 70 mg; dextrose, hydrous 37.5 mg; benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment.
pH 6.3 (5.0 to 7.0). DOSAGE: See Prescribing Information. Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.]

Distributed by Hospira, Inc.
Lake Forest, IL 60045 USA

Hospira

PAA244655



PRINCIPAL DISPLAY PANEL - 1 mL Ampul Label - novaplus

NDC 0409-9158-11
Rx only

1 mL Single-dose Ampul

VITAMIN K_1 Inj.
(Phytonadione Injectable
Emulsion, USP)
10 mg/mL

Contains no more than 110 mcg/L
of aluminum. Protect from light.
Dist. by Hospira, Inc.
Lake Forest, IL 60045 USA

novaplus™

PAA244652

AA####
YYYY-MMM



PRINCIPAL DISPLAY PANEL - 1 mL Ampul Tray Label - novaplus

1 mL Single-dose Ampul
Rx only
NDC 0409-9158-55
Contains 5 of NDC 0409-9158-11

VITAMIN K_1 Injection
(Phytonadione Injectable Emulsion, USP)

10 mg/mL

For Intramuscular, Subcutaneous, or Intravenous (with caution).

Protect from light. Keep ampuls in tray until time of use.
Each mL contains phytonadione 10 mg; polyoxyethylated fatty acid derivative 70 mg; dextrose, hydrous 37.5 mg; benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment.
pH 6.3 (5.0 to 7.0). DOSAGE: See Prescribing Information. Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.]
Distributed by Hospira, Inc.
Lake Forest, IL 60045 USA
Novaplus is a registered
trademark of Vizient, Inc.

PAA244530

novaplus™



VITAMIN K1

phytonadione injection, emulsion

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:0409-9157
Route of Administration	INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857)	PHYTONADIONE	2 mg in 1 mL

Inactive Ingredients	
Ingredient Name	**Strength**
POLYOXYL 35 CASTOR OIL (UNII: 6D4M1DAL6O)	70 mg in 1 mL
DEXTROSE MONOHYDRATE (UNII: LX22YL083G)	37.5 mg in 1 mL

WATER (UNII: 059QF0KO0R)	
BENZYL ALCOHOL (UNII: LKG8494WBH)	9 mg in 1 mL
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0409-9157-01	5 in 1 CONTAINER	06/22/2005	
1	NDC:0409-9157-50	5 in 1 TRAY		
1	NDC:0409-9157-31	0.5 mL in 1 AMPULE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA087954	06/22/2005	

VITAMIN K1

phytonadione injection, emulsion

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:0409-9158
Route of Administration	INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857)	PHYTONADIONE	10 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
POLYOXYL 35 CASTOR OIL (UNII: 6D4M1DAL6O)	70 mg in 1 mL
DEXTROSE MONOHYDRATE (UNII: LX22YL083G)	37.5 mg in 1 mL
WATER (UNII: 059QF0KO0R)	
BENZYL ALCOHOL (UNII: LKG8494WBH)	9 mg in 1 mL
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Packaging

#	Item Code	Package Description	Marketing Start	Marketing End

#	Item Code	Package Description	Date	Date
1	NDC:0409-9158-01	5 in 1 CONTAINER	07/27/2005	
1	NDC:0409-9158-50	5 in 1 TRAY		
1	NDC:0409-9158-31	1 mL in 1 AMPULE; Type 0: Not a Combination Product		
2	NDC:0409-9158-25	5 in 1 CONTAINER	01/15/2021	
2	NDC:0409-9158-55	5 in 1 TRAY		
2	NDC:0409-9158-11	1 mL in 1 AMPULE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA087955	07/27/2005	

Labeler - Hospira, Inc. (141588017)

Establishment

Name	Address	ID/FEI	Business Operations
Hospira, Inc.		093132819	ANALYSIS(0409-9157, 0409-9158) , MANUFACTURE(0409-9157, 0409-9158) , PACK(0409-9157, 0409-9158) , LABEL(0409-9157, 0409-9158)

Establishment

Name	Address	ID/FEI	Business Operations
Hospira, Inc.		030606222	ANALYSIS(0409-9157, 0409-9158)

Revised: 8/2026 Hospira, Inc.